Beijing InnoCare Pharma Tech Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS23
PHASE 3 / 2-310
RECRUITING16
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO50%
Delay Index: of 10 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.2 months). See all sponsors →
Open Beijing InnoCare Pharma Tech Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Tafasitamab and Lenalidomide NCT05552937 |
P2 | Recruiting | DLBCL | 50 | 2025-04 |
| ICP-192 NCT05678270 |
P2 | Recruiting | Intrahepatic Cholangiocarcinoma (ICC) | 70 | 2026-05 |
| ICP-488 Tablets NCT06842199 |
P3 | Recruiting | Plaque Psoriasis Patients | 383 | 2026-05 |
| Orelabrutinib (ICP-022) NCT04014205 |
P1/2 | Active, not recruiting | Part 1:r/r B-cell Malignancies; Part 2:B-cell Malignancies | 81 | 2026-06-30 (+70 mo) |
| ICP-332 Tablets NCT06775860 |
P3 | Recruiting | Atopic Dermatitis | 552 | 2026-11-25 |
| CM355 NCT05210868 |
P1/2 | Active, not recruiting | Hematoma | 184 | 2026-12-28 |
| ICP-322 NCT07236099 |
P2 | Recruiting | Prurigo Nodularis (PN) | 135 | 2027-03 |
| ICP-488 Tablets NCT07440537 |
P2 | Recruiting | Cutaneous Lupus Erythematosus (CLE) | 105 | 2027-03 |
| ICP-B381 NCT07901413 |
P1/2 | Not yet recruiting | Advanced Solid Tumor | 348 | 2027-09 |
| ICP-248 NCT07082686 |
P2 | Recruiting | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | 75 | 2027-12 (+24 mo) |
| ICP-723 NCT05745623 |
P1/2 | Recruiting | Advanced Solid Tumors Harboring NTRK Fusion; Primary Central Nervous System Tumors Harboring NTRK Fusion | 70 | 2027-12-25 (+43 mo) |
| ICP-723 NCT04685226 |
P1/2 | Recruiting | Solid Tumors | 310 | 2028-01-25 (+61 mo) |
| ICP-490 NCT06845241 |
P1/2 | Not yet recruiting | Relapsed or Refractory Non-Hodgkin Lymphoma | 68 | 2028-07 |
| Orelabrutinib NCT06082102 |
P3 | Recruiting | Relapsed/Refractory Marginal Zone Lymphoma | 324 | 2028-08-31 (+12 mo) |
| Tafasitamab NCT06521255 |
P3 | Recruiting | DLBCL | 244 | 2028-09 |
| ICP-332 Tablets NCT07378527 |
P2/3 | Recruiting | Chronic Spontaneous Urticaria (CSU) | 344 | 2028-09 |
| Orelabrutinib NCT07896590 |
P3 | Not yet recruiting | Relapsed/Refractory Marginal Zone Lymphoma (MZL) | 292 | 2028-10 |
| ICP-488 Tablets NCT07727486 |
P2 | Not yet recruiting | Primary Sjögren's Syndrome | 240 | 2028-12 |
| ICP-332 Tablets NCT07047612 |
P2/3 | Recruiting | Non Segmental Vitiligo | 603 | 2029-04 |
| Mesutoclax (ICP-248) NCT07925190 |
P3 | Recruiting | Acute Myeloblastic Leukemia | 318 | 2029-12 |
| ICP-248 NCT06378138 |
P2/3 | Recruiting | Hematologic Malignancies | 226 | 2030-11-25 |
| ICP-B208 NCT07617493 |
P1/2 | Recruiting | Advanced Solid Tumor | 551 | 2030-12 |
| ICP-248 NCT07784101 |
P3 | Not yet recruiting | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | 280 | 2032-10 |